Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...

The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...